The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
- 28 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (3) , 353-563
Abstract
Objective: To assess the effects of decreased antiretroviral therapy exposure on body fat and metabolic parameters. Design: Substudy of the Strategies for Management of Anti-Retroviral Therapy study, in which participants were randomized to intermittent CD4-guided [Drug Conservation (DC) group] or to continuous [Viral Suppression (VS) group] antiretroviral therapy. Methods: Participants at 33 sites were coenrolled in the Strategies for Management of Anti-Retroviral Therapy Body Composition substudy. Regional fat was assessed annually by whole-body dual-energy X-ray absorptiometry and abdominal computed tomography. Fasting metabolic parameters were assessed at months 4, 8, and annually. Treatment groups were compared for changes in fat and metabolic markers using longitudinal mixed models. Results: Two hundred and seventy-five patients were randomized to the DC (n = 142) or VS (n = 133) group and followed for a median of 2.0 years. By month 12, limb fat (DC-VS difference 9.8%, 95% confidence interval 3.5–16.1; P = 0.003) and subcutaneous abdominal fat (DC-VS difference 14.3 cm2, 95% confidence interval −0.1 to 28.7; P = 0.05) increased in the DC group. There was no treatment difference in visceral abdominal fat (DC-VS difference −2.1%, 95% confidence interval −13.5 to 9.4; P = 0.72). Lipids significantly decreased in the DC group by month 4 and treatment differences persisted throughout follow-up (P ≤ 0.001). By 12 months, hemoglobin A1C increased in the DC (+0.3%) and remained stable in the VS group (P = 0.003); the treatment difference remained significant throughout follow-up (P = 0.02). Conclusion: After 12 months, intermittent antiretroviral therapy increased subcutaneous fat, had no effect on visceral abdominal fat, decreased plasma lipids, and increased hemoglobin A1C compared with continuous antiretroviral therapy.Keywords
This publication has 39 references indexed in Scilit:
- A1C Underestimates Glycemia in HIV InfectionDiabetes Care, 2009
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV InfectionPLOS Medicine, 2008
- Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular RiskPLOS ONE, 2008
- CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialThe Lancet, 2006
- Structured Intermittent Interruption of Chronic HIV Infection Treatment with Highly Active Antiretroviral Therapy: Effects on Leptin and TNF- αAIDS Research and Human Retroviruses, 2006
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Case Study: Potential Pitfalls of Using Hemoglobin A1c as the Sole Measure of Glycemic ControlClinical Diabetes, 2004
- Inaccurate Glycosylated Hemoglobin A1C Measurements in Human Immunodeficiency Virus—Positive Patients with Diabetes MellitusClinical Infectious Diseases, 2003
- Lipids, diabetes, and coronary heart disease: Insights from the Framingham StudyAmerican Heart Journal, 1985